Table 2.
Main follow-up outcomes
| Outcomes | n = 71 |
|---|---|
| Follow-up (days), median (IQR) | 17 (12–23) |
| ICU length of stay (n = 38)a, median (IQR) | 10 (6.7–14.2) |
| Intubation, n (%) | 55/71 (77) |
| Length of intubation (n = 29)b, median (IQR) | 12 (9–17) |
| Worst PaO2/FiO2, median (IQR) | 95 (79–125) |
| Need for NE infusion, n (%) | 52/71 (73) |
| Maximal dose of NE infusion (µg/kg/min), median (IQR) | 0.16 (0.10–0.37) |
| Day of NE maximal dose from ICU admission (days), median (IQR) | 4 (1–12) |
| Maximal lactate level (mmol/L), mean ± SD | 1.5 ± 0.7 |
| ICU deaths, n (%) | 4/71 (6) |
| Onset of death from ICU admission (days), median (IQR) | 9 (5–19) |
a
The ICU length of stay was only calculated for patients who were discharged from the ICU, n = 38.
b
The length of intubation was only calculated for patients who were successfully weaned from the ventilator, n = 29.
FiO2, fraction of inspired oxygen; ICU, intensive care unit; NE, norepinephrine; PaO2, arterial partial pressure of oxygen.